SG11202007755YA - Cd83-binding chimeric antigen receptors - Google Patents

Cd83-binding chimeric antigen receptors

Info

Publication number: SG11202007755YA
Authority: SG; Singapore
Prior art keywords: chimeric antigen; antigen receptors; binding chimeric; binding; receptors
Prior art date: 2018-02-23

Application number

SG11202007755YA

Inventor

Marco Davila

Brian Betts

Original Assignee

H Lee Moffitt Cancer Ct & Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-02-23

Filing date

2019-02-22

Publication date

2020-09-29

2019-02-22 Application filed by H Lee Moffitt Cancer Ct & Res filed Critical H Lee Moffitt Cancer Ct & Res

2020-09-29 Publication of SG11202007755YA publication Critical patent/SG11202007755YA/en

Links

108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
101100438949 Mus musculus Cd83 gene Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

SG11202007755YA 2018-02-23 2019-02-22 Cd83-binding chimeric antigen receptors SG11202007755YA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201862634435P	2018-02-23	2018-02-23
US201862677783P	2018-05-30	2018-05-30
PCT/US2019/019065 WO2019165156A1 (en)	2018-02-23	2019-02-22	Cd83-binding chimeric antigen receptors

Publications (1)

Publication Number	Publication Date
SG11202007755YA true SG11202007755YA (en)	2020-09-29

Family

ID=67686942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202007755YA SG11202007755YA (en)	2018-02-23	2019-02-22	Cd83-binding chimeric antigen receptors

Country Status (15)

Country	Link
US (1)	US20210032336A1 (en)
EP (1)	EP3755722A4 (en)
JP (1)	JP7358369B2 (en)
KR (1)	KR20200130324A (en)
CN (1)	CN112004832A (en)
AU (1)	AU2019226101A1 (en)
BR (1)	BR112020017015A2 (en)
CA (1)	CA3092220A1 (en)
IL (1)	IL276836A (en)
MA (1)	MA51917A (en)
MX (1)	MX2020008803A (en)
PH (1)	PH12020500632A1 (en)
SG (1)	SG11202007755YA (en)
WO (1)	WO2019165156A1 (en)
ZA (1)	ZA202005837B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20220289862A1 (en) *	2019-08-16	2022-09-15	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Anti-cd83 chimeric antigen receptor expressing t regulatory cells
US20220289813A1 (en) *	2019-08-16	2022-09-15	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Chimeric antigen receptors for treating myeloid malignancies
US11802159B2 (en) *	2019-09-30	2023-10-31	The Trustees Of The University Of Pennsylvania	Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs)
WO2021127212A2 (en) *	2019-12-18	2021-06-24	H. Lee Moffitt Cancer Center And Research Institute Inc.	Systems and methods for producing efficacious regulatory t cells
US20230390391A1 (en) *	2020-01-22	2023-12-07	Regents Of The University Of Minnesota	Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
US20230107770A1 (en) *	2020-02-20	2023-04-06	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Method of enhancing immunotherapy using er stress pathway inhibitors
WO2022036224A1 (en) *	2020-08-14	2022-02-17	H. Lee Moffitt Cancer Center And Research Institute Inc.	Chimeric antigen receptor t cells for treating autoimmunity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040185040A1 (en) *	2001-11-21	2004-09-23	Celltech R & D Limited	Modulating immune responses
JP2013150592A (en)	2011-07-01	2013-08-08	Genentech Inc	Use of anti-cd83 agonist antibody for treating autoimmune disease
JP2013040160A (en)	2011-07-01	2013-02-28	Genentech Inc	Use of anti-cd83 agonist antibody for treating autoimmune disease
CA2899960C (en)	2013-02-01	2022-05-03	Transbio Ltd	Anti-cd83 antibodies and use thereof
US10870704B2 (en)	2014-10-23	2020-12-22	Kira Biotech Pty Limited	CD83 binding proteins and uses thereof
WO2016070061A1 (en) *	2014-10-31	2016-05-06	The Trustees Of The University Of Pennsylvania	Methods and compositions for modified t cells
CN107708741A (en)	2015-06-12	2018-02-16	免疫医疗公司	The physics carried out with the T cell (CAR T) or NK cells (CAR NK) of Chimeric antigen receptor (CAR) construct and expression CAR constructs
SG10201913682QA (en) *	2015-06-25	2020-03-30	Icell Gene Therapeutics Llc	CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
EP3423482A1 (en) *	2016-03-04	2019-01-09	Novartis AG	Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore

2019
- 2019-02-22 JP JP2020543928A patent/JP7358369B2/en active Active
- 2019-02-22 WO PCT/US2019/019065 patent/WO2019165156A1/en unknown
- 2019-02-22 CN CN201980027877.0A patent/CN112004832A/en active Pending
- 2019-02-22 MX MX2020008803A patent/MX2020008803A/en unknown
- 2019-02-22 BR BR112020017015-1A patent/BR112020017015A2/en unknown
- 2019-02-22 KR KR1020207027148A patent/KR20200130324A/en active Search and Examination
- 2019-02-22 CA CA3092220A patent/CA3092220A1/en active Pending
- 2019-02-22 EP EP19757555.8A patent/EP3755722A4/en active Pending
- 2019-02-22 SG SG11202007755YA patent/SG11202007755YA/en unknown
- 2019-02-22 US US16/969,056 patent/US20210032336A1/en active Pending
- 2019-02-22 AU AU2019226101A patent/AU2019226101A1/en not_active Abandoned
- 2019-02-22 MA MA051917A patent/MA51917A/en unknown
2020
- 2020-08-19 PH PH12020500632A patent/PH12020500632A1/en unknown
- 2020-08-20 IL IL276836A patent/IL276836A/en unknown
- 2020-09-21 ZA ZA2020/05837A patent/ZA202005837B/en unknown

Also Published As

Publication number	Publication date
PH12020500632A1 (en)	2021-05-10
CA3092220A1 (en)	2019-08-29
JP7358369B2 (en)	2023-10-10
MA51917A (en)	2021-06-02
EP3755722A4 (en)	2021-11-24
ZA202005837B (en)	2023-02-22
WO2019165156A1 (en)	2019-08-29
IL276836A (en)	2020-10-29
BR112020017015A2 (en)	2020-12-15
CN112004832A (en)	2020-11-27
EP3755722A1 (en)	2020-12-30
JP2021513857A (en)	2021-06-03
AU2019226101A1 (en)	2020-09-17
US20210032336A1 (en)	2021-02-04
KR20200130324A (en)	2020-11-18
MX2020008803A (en)	2021-01-15

Publication	Publication Date	Title
IL276396A (en)	2020-09-30	Chimeric antigen receptors targeting cd70
IL277078A (en)	2020-10-29	Anti-cd33 chimeric antigen receptors and their uses
IL280029A (en)	2021-03-01	Ror-1 specific chimeric antigen receptors and uses thereof
EP3528851A4 (en)	2020-06-03	Cereblon-based heterodimerizable chimeric antigen receptors
EP3134434A4 (en)	2017-10-25	Kappa/lambda chimeric antigen receptors
GB201617290D0 (en)	2016-11-23	Novel chimeric antigen receptors
IL270896A (en)	2020-01-30	Chimeric antigen receptors targeting flt3
ZA202005837B (en)	2023-02-22	Cd83-binding chimeric antigen receptors
IL280033A (en)	2021-03-01	Uses of anti-bcma chimeric antigen receptors
GB201607968D0 (en)	2016-06-22	Chimeric antigen receptor
IL279310A (en)	2021-01-31	Cd79a chimeric antigen receptors
GB201610512D0 (en)	2016-08-03	Chimeric antigen receptor
GB201807870D0 (en)	2018-06-27	A CD79-specific chimeric antigen receptor
ZA201906321B (en)	2021-02-24	Chimeric antigen receptor
IL285587A (en)	2021-09-30	Hypoxia-responsive chimeric antigen receptors
IL285909A (en)	2021-10-31	Anti-bcma chimeric antigen receptors
IL281428A (en)	2021-04-29	Chimeric antigen receptor
IL287310A (en)	2021-12-01	Antibodies against 4g7-derived chimeric antigen receptors
EP3585403A4 (en)	2020-12-09	Tim3-binding chimeric antigen receptors
GB201801831D0 (en)	2018-03-21	Chimeric receptor
GB201709508D0 (en)	2017-08-02	Chimeric antigen receptor
GB201711470D0 (en)	2017-08-30	Chimeric receptors
GB201807862D0 (en)	2018-06-27	Chimeric antigen receptor
IL287487A (en)	2021-12-01	Rituximab-resistant chimeric antigen receptors and uses thereof
IL277859A (en)	2020-11-30	Chimeric notch receptors